Strengths and limitations of this study 62
• This is the first systematic review assessing user involvement for adolescents' mental 63 healthcare 64
• Established guidelines are used for data retrieval, data extraction, critical appraisal, data 65 synthesis and reporting of results 66
• Adolescents are involved as co-researchers through all phases of the systematic review 67
• Wide inclusion criteria may represent challenges for synthesizing the research evidence, 68 although it will also provide a more extensive overview of the research literature 69
• We expect to find limited research evidence in this field, which may also limit the extent to 70 which we will be able to provide recommendations for clinical practice 71 Mental health disorders affect a significant proportion of adolescents in countries all around the 75 world. On average, 13.4 % (CI 95 % 11.3-15.9) in the age groups up to 18 years suffer from mental 76 disorders, according to a meta-analysis of prevalence studies in 27 countries. 1 In many instances 77 these complaints result in functional impairment. The age group from 10 to 24 years represents 16 % 78 of all disability adjusted life years (DALYs) of all age groups and. adolescents have a right of access to high quality and safe healthcare services and their views must 82 be heard and considered in any matters affecting them.
3,4 Although parents commonly have the 83 authority to make decisions on behalf of their children, some national legislative frameworks (e.g. in 84
Canada, Ireland and the United Kingdom) also emphasize children's right to be heard and actively 85 involved in decision-making concerning their own health. 5 Adolescents at the age of 16 are in some 86 countries considered to be competent and have the right to consent to or refuse treatment. This may 87 in some instances extend down to the age of 12 (e.g. in Ireland, Netherlands, UK) or younger (e.g. in 88
Canada, New Zealand, South Africa), provided they are able to fully understand what the 89 interventions involve. Some of the basic principles underpinning national legislation and regulations 90 include respect, taking the adolescent seriously, encouraging cooperation and encouraging 91 adolescents to take responsibility for their own health. 92 93 Patient-and person-centered or person-directed care with patient or service user involvement has 94 become increasingly common in various fields of healthcare and at various levels. The term patient-95 centered care was initially described as focusing on the patient as a whole, including both physical 96 and psychological aspects. 6 It requires a more active and participating role on the part of the 97 practitioner, compared to a more illness-oriented approach with uninvolved objective observation. In 98 later years, the understanding of patient-centered care has taken into account service users' needs, 99 priorities and expectations of healthcare services, and can lead to reorganization of services. 7 A 100 person-centered approach moves one step further by taking the whole person into consideration, 101 including mental, emotional, spiritual and social needs, and in a person-directed approach individuals 102 take control of decisions affecting their own care. to take users' views and wishes into account. 10 When managed well, these processes may contribute 115 to shared decision-making and self-determination for patients' healthcare services, provided within a 116 context of person-centered or person-directed care. The active involvement of service users in healthcare decision-making has the potential to contribute 119 to user empowerment and improvement of the quality and safety of healthcare systems. 11 National 120 legislation and regulation in many countries requires healthcare services to involve users in their own 121 treatment, as well as at an institutional/organizational and political level. This includes various areas 122 associated with mental healthcare, for example in development of healthcare policies and 123 strategies, 12 for implementation of clinical guidelines, 13 in education of health professionals, 14 and for 124 employment of healthcare staff and user-to-user panels. 15 It has been suggested that users should be 125 involved at every mental healthcare service level. 16 
127
Little is known about the existing research evidence reporting on user involvement for adolescents' 128 mental healthcare. A literature search carried out in 2012 with an aim to assess the existing evidence 129 of children's and adolescents' engagement in decision-making for their own healthcare, identified 130 only a handful of studies, in asthma, HIV, cancer, learning and behavior problems, and sun protection 131 behaviors. 17 No systematic review has focused specifically on user involvement in adolescents' 132 mental healthcare. 133 134 A number of important research questions need clarification, such as: What efforts are commonly 135 put into place to encourage user involvement in adolescents' mental healthcare and how do they 136 perceive such efforts? User involvement is commonly perceived to contribute positively to clinical 137 treatment outcomes and some research suggests shared decision-making for individuals ' 
METHODS

160
We will use pre-defined eligibility criteria and search strategies, and guidelines for data extraction, 161 critical appraisal, data synthesis and reporting of results. 162
163
Eligibility criteria 164 165
The inclusion criteria for this systematic review are: Studies reporting on experiences with, 166 effectiveness of and safety issues associated with user involvement (intervention) in the planning, 167 delivery and development of adolescents' mental healthcare (participants). Users may be 168 adolescents or their caretakers. Mental healthcare may include preventive or therapeutic 169 interventions for diagnosed conditions or self-reported problems. User involvement may be aimed at 170 the individual level (for adolescents' own healthcare), at the organizational or institutional level (to 171 improve healthcare services/institutions), or at the political level (for making political decisions). It is 172 unlikely that the effectiveness of user involvement has been tested in randomized controlled trials. 173
We are therefore including non-randomized trials and studies (NRS). We are not limiting the 174 literature search to any specific research methods, as this may lead to missing studies in systematic 175 reviews including NRS. 21 
207
A minimum of two reviewers will screen titles and abstracts to determine inclusion/exclusion of 208 articles. All potentially relevant full text articles will be read and assessed according to the 209 inclusion/exclusion criteria. In the event of continued doubt, a third reviewer will be included for 210 consensus or majority vote decisions. Reasons for exclusion will be logged. Endnote (version X8) will 211 be used to manage data records. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 25 A second reviewer will check the accuracy of input 219 data. Cross-references to article publications may be used, but authors of original trials and studies 220
will not be contacted for clarification as this may lead to too optimistic and biased responses. 26 For 221 studies reporting on the effectiveness of interventions, a main outcome will be identified as defined 222 by the authors of the original article. Reviewers will decide on which outcome measure to report in 223 the event that no main outcome has been defined by study authors, as well as any additional 224 outcomes of importance to users. 225
226
Critical appraisal 227 228
Including studies and trials using various research methods could potentially result in misleading 229 effect estimates. 21 To avoid this, we will use the Cochrane Collaboration's guidelines to assess risk of 230 bias at the outcome level. 26 We will assess the risk of selection bias, performance bias, detection 231 bias, attrition bias and reporting bias. Particular attention will be paid to the potential influence of 232 confounding factors for NRS, as suggested by the Cochrane Collaboration. 21 Moreover, we will assess 233 the risk of meta-bias by searching for unpublished studies in the grey literature; by comparing 234 protocols articles with results articles; and by assessing methods and results sections of individual 235 study articles. If there is a sufficient number of studies (min. 10) with variation in trial sizes (at least 236 one medium or large), funnel plot symmetry together with a regression analysis will be assessed to 237 consider risk of publication bias, as suggested by Sterne et al. 27 However, whether a trial is free of 238 bias does not address the question of its applicability and generalizability to end users, including 239 patients, clinicians and policy makers. 28 We will therefore assess the external validity of trials using 240 the PRECIS tool. 29 The Critical Appraisal Skills Programme (CASP) will be used for assessing qualitative 241 studies. 25 
243
The confidence in the evidence resulting from the identified research literature will be assessed using 244 the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The extent to which data will be synthesized, will depend on the degree of homogeneity of included 251 studies. We will determine consistency of the evidence by assessing the variability of trials. Particular 252 attention will be paid to clinical aspects (e.g. interventions, clinical conditions) and research methods. 253
The effect of heterogeneity will be quantified using the I 2 statistic to calculate variability across 254 trials. 31 
256
In the event of sufficient homogeneity, results of randomized trials will be presented collectively 257 through a meta-analysis, presenting effect estimates with standard errors or confidence intervals. A 258 summary statistic will be calculated for the main outcome in each trial, determining the risk ratio for 259 dichotomous outcomes and standardized mean differences for continuous outcomes (both with 95 % 260 confidence intervals). A weighted average will be calculated to determine the overall treatment 261 effect in the included trials. We expect at least some heterogeneity between trials and will therefore 262 apply a random effects model to estimate the mean of the distribution of effects. Analysis of sub-263 groups will be considered for specific clinical conditions (e.g. depression, anxiety or psychosis), for 264 particular research methods (e.g. randomized controlled trials, cluster randomized trials or non-265 randomized studies and trials), and if the I 2 statistic supersedes 40 %. For groups of NRS applying 266 similar study designs, summarized adjusted effect estimates will be presented (controlling for 267 confounding factors) as suggested by Reeves et al. 21 Only a narrative summary will be developed in 268 the event of considerable heterogeneity (I 2 >75%). Dependent on a sufficient number of included 269 studies, qualitative studies will be synthesized. 32 Some flexibility is needed with regards to choice of 270 the most suitable approach for the qualitative synthesis as this will depend on the available research 271 evidence, in particular with regards to the quality and heterogeneity of studies. We will therefore 272 make a final decision to determine the synthesis approach after collection of data, but will aim at 273 applying either a textual narrative synthesis or a thematic analytic synthesis approach. 
Reporting results 276 277
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and 278 flow diagram will be used to report the result of literature searches. 35 Results of randomized 279 controlled trials will be reported according to the CONSORT statement, 36 for observational studies 280 the STROBE statement, 24 and for qualitative studies the CASP checklist. 25 Results of all studies will be 281 presented in tables, providing information on study design, results and quality of evidence. Separate 282 tables will be provided in the event of different subgroups of patients. We will report results 283 collectively for comparative (sufficiently homogenous) studies, grouped according to their associated 284 risk of bias. Results will be presented separately for randomized controlled trials and NRS. Moreover, 285 User involvement has become a priority in healthcare systems in many countries, as it is considered a 300 citizen right to be involved in decisions affecting one's own healthcare. Although several systematic 301 reviews have summarized existing evidence in user involvement in health research for adults in 302 general or in areas such as safety and education of mental health professionals, 37-39 little is known 303 about user involvement for adolescents' mental healthcare. This systematic review therefore aims to 304 fill an existing knowledge gap. It will provide an insight into users' experiences, effectiveness of and 305 safety issues associated with user involvement at an individual level for adolescents' own healthcare, 306 at an organizational or institutional level for improvement of healthcare services and institutions, and 307 at the political level for political decision-making processes. It may thereby provide information that 308 can be valuable for several stakeholder groups, such as patients and their families, healthcare 309 providers, clinicians and decision makers, as well as for developing research strategies to further 310 knowledge in an underexplored field of research. This may include knowledge about ways in which 311 users are involved in decision-making affecting their own healthcare and the influence of such 312 involvement on their health outcomes. It can also provide information on user involvement affecting 313 delivery and healthcare service policy decisions. 314
315
There is considerable variation in the literature with regards to used terminology relating to user 316 involvement. We have, in an attempt to capture the relevant research literature, included several 317 search strategies using a variety of search terms. Moreover, we hope to capture most of the 318 literature relevant to adolescents, although research carried out with varying age groups (single 319 studies reporting on both children and adolescents, or adolescents and young people) may limit the 320 We have chosen UNICEF's definition of adolescents, thereby including any studies reporting on 323 results in the age group ranging from 10 to 19 years. The results of this review will therefore not be 324 applicable to children under the age of 10 or young persons above the age of 19 years. 325 326 A limitation of this systematic review is the restriction to only six languages. Although we expect to 327 capture most of the published research literature through English language articles, and although 328 some evidence suggests reduced importance of non-English language articles for assessing the 329 effectiveness of interventions, 40 we cannot exclude the possibility that significant literature has been 330 published in other languages. We have added five languages in an attempt to limit the gaps in the 331 research evidence collected through our review. Our choice of languages is partly due to the strong 332 tradition user involvement has in some of these countries, but is nevertheless limited by our 333 available resources. The inclusion of a wide range of databases increases the likelihood of capturing 334 most of the relevant literature in this field of research. Moreover, the inclusion of databases more 335 specifically covering the Nordic literature will increase the chance of also capturing the evidence 336 published in these countries. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This checklist has been adapted for use with protocol submissions to Systematic Reviews from Table 3 
METHODS
Eligibility criteria 8
Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
164-184
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage
186-195
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated Appendix A
STUDY RECORDS
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 207-219
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
207-211
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
215-224
Data items 12 List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications
166-179
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 178, 220-224
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Ethics and dissemination: Ethics approval is not required for this systematic review as we are not 46 collecting primary data. The results will be published in a peer-reviewed journal and at conference 47 presentations, and will be shared with stakeholder groups. 48 49 Keywords: User involvement; adolescents; mental health; systematic review; protocol 50 51
229-237
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Synthesis
Strengths and limitations of this study 52
• This is the first systematic review assessing user involvement for adolescents' mental 53 healthcare 54
• Established guidelines are used for data retrieval, data extraction, critical appraisal, data 55 synthesis and reporting of results 56
• Adolescents are involved as co-researchers through all phases of the systematic review 57 although it will also provide a more extensive overview of the research literature 59
• We expect to find limited research evidence in this field, which may also limit the extent to 60 which we will be able to provide recommendations for clinical practice 61 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 become increasingly common in various fields of healthcare and at various levels. The term patient-85 centered care was initially described as focusing on the patient as a whole, including both physical 86 and psychological aspects. 6 It requires a more active and participating role on the part of the 87 practitioner, compared to a more illness-oriented approach with uninvolved objective observation. In 88 later years, the understanding of patient-centered care has taken into account service users' needs, 89 priorities and expectations of healthcare services, and can lead to reorganization of services. 7 A 90 person-centered approach moves one step further by taking the whole person into consideration, 91 including mental, emotional, spiritual and social needs, and in a person-directed approach individuals 92 take control of decisions affecting their own care. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 problems. User involvement may be aimed at the individual level (for adolescents' own mental 168 healthcare) or at the organizational or institutional level (to improve mental healthcare 169 services/institutions). It is unlikely that the effectiveness of user involvement has been tested in 170 randomized controlled trials. We will therefore include non-randomized trials and studies (NRS). 171 Additionally, we will not limit the literature search to any specific research methods, as this may lead 172 to missing studies in systematic reviews including NRS. 24 Studies may include any research design 173 (qualitative or quantitative) used to answer the research questions of this review, and may or may 174 not include comparators/control groups (control). Outcomes will be reported according to the 175 original trials and studies. Adolescents' user involvement may have been reported by adolescents, 176 their caretakers, health professionals or other stakeholder groups. Adolescents will be defined as the 177 age group from 13 to 18 years (MeSH Unique ID: D000293). Studies reporting on adolescents and 178 children or adults will be included if data for adolescents can be extracted and analysed separately. 179
Results or the peer-reviewed and the grey literature will be reported separately. Exclusion criteria: 180
Debate, commentaries, editorials, studies reporting on children (age below 13) or adults (age above 181 18). Languages will be limited to English, French, German, Danish, Norwegian and Swedish. The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 A minimum of two reviewers will screen titles and abstracts to determine inclusion/exclusion of 206 articles. All potentially relevant full text articles will be read and assessed by at least two reviewers 207 according to the inclusion/exclusion criteria. In the event of continued doubt, a third reviewer will be 208 included for consensus or majority vote decisions. Reasons for exclusion will be logged. Endnote 209 (version X8) will be used to manage data records. 210
211
Data extraction 212 213
Data will be extracted and input by one reviewer into an Excel spreadsheet using the Cochrane 214
Consumers and Communication Review Group's data extraction template for trials; 25 the STROBE 215 statement checklist for cohort, case-control and cross-sectional studies; 26 and the Critical Appraisal 216 Skills Programme (CASP) for qualitative studies. 27 A second reviewer will check the accuracy of input 217 data. Cross-references to article publications may be used, but authors of original trials and studies 218
will not be contacted for clarification as this may lead to too optimistic and biased responses. 28 For 219 studies reporting on the effectiveness of interventions, a main outcome will be identified as defined 220 by the authors of the original article. Reviewers will decide on which outcome measure to report in 221 the event that no main outcome has been defined by study authors, as well as any additional 222 outcomes of importance to users. 223
224
Critical appraisal 225 226
Including studies and trials using various research methods could potentially result in misleading 227 effect estimates. 24 To avoid this, we will use the Cochrane Collaboration's guidelines to assess risk of 228 bias at the outcome level. 28 We will assess the risk of selection bias, performance bias, detection 229 bias, attrition bias and reporting bias. Particular attention will be paid to the potential influence of 230 confounding factors for NRS, as suggested by the Cochrane Collaboration. 24 Moreover, we will assess 231 the risk of meta-bias by searching for unpublished studies in the grey literature; by comparing 232 protocols articles with results articles; and by assessing methods and results sections of individual 233 study articles. If there is a sufficient number of studies (min. 10) with variation in trial sizes (at least 234 one medium or large), funnel plot symmetry together with a regression analysis will be assessed to 235 consider risk of publication bias, as suggested by Sterne et al. 29 However, whether a trial is free of 236 bias does not address the question of its applicability and generalizability to end users, including 237 patients, clinicians and policy makers. 30 We will therefore assess the external validity of trials using 238 the PRECIS tool. 31 The Critical Appraisal Skills Programme (CASP) will be used for assessing qualitative 239 studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The extent to which data will be synthesized, will depend on the degree of homogeneity of included 249 studies. We will determine consistency of the evidence by assessing the variability of trials. Particular 250 attention will be paid to clinical aspects (e.g. interventions, clinical conditions) and research methods. 251
The effect of heterogeneity will be quantified using the I 2 statistic to calculate variability across 252 trials. In the event of sufficient homogeneity, results of randomized trials will be presented collectively 255 through a meta-analysis, presenting effect estimates with standard errors or confidence intervals. A 256 summary statistic will be calculated for the main outcome in each trial, determining the risk ratio for 257 dichotomous outcomes and standardized mean differences for continuous outcomes (both with 95 % 258 confidence intervals). A weighted average will be calculated to determine the overall treatment 259 effect in the included trials. We expect at least some heterogeneity between trials and will therefore 260 apply a random effects model to estimate the mean of the distribution of effects. Analysis of sub-261 groups will be considered for specific clinical conditions (e.g. depression, anxiety or psychosis), for 262 particular research methods (e.g. randomized controlled trials, cluster randomized trials or non-263 randomized studies and trials), and if the I 2 statistic supersedes 40 %. For groups of NRS applying 264 similar study designs, summarized adjusted effect estimates will be presented (controlling for 265 confounding factors) as suggested by Reeves et al. 24 Only a narrative summary will be developed in 266 the event of considerable heterogeneity (I 2 >75%). Dependent on a sufficient number of included 267 studies, qualitative studies will be synthesized. 34 Some flexibility is needed with regards to choice of 268 the most suitable approach for the qualitative synthesis as this will depend on the available research 269 evidence, in particular with regards to the quality and heterogeneity of studies. We will therefore 270 make a final decision to determine the synthesis approach after collection of data, but will aim at 271 applying either a textual narrative synthesis or a thematic analytic synthesis approach. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and 276 flow diagram will be used to report the result of literature searches. 37 Results of randomized 277 controlled trials will be reported according to the CONSORT statement, 38 for observational studies 278 the STROBE statement, 26 and for qualitative studies the CASP checklist. 27 Results of all studies will be 279 presented in tables, providing information on study design, results and quality of evidence. Separate 280 tables will be provided in the event of different subgroups of patients. We will report results 281 collectively for comparative (sufficiently homogenous) studies, grouped according to their associated 282 risk of bias. Results will be presented separately for randomized controlled trials and NRS. Moreover, 283 the nature of the data will also warrant presentation of results according to research methods (e.g. 284 results of qualitative and quantitative studies will be reported separately). Information on 285 methodological decisions made or modified after data collection will be reported. Moreover, we will 286 report involvement of user/interest groups, experts and researchers. 287 We have participated in the process of developing the systematic review and we will contribute in 301 the review process and for publishing the results. We have agreed to be asked for our opinion on 302 articles the other researchers consider including, their evaluation of the content and quality of the 303 articles, and how results will be reported. We will also publish a lay summary of the results on a 304
Facebook site we are setting up for the research project. 305
306
We expressed our interest in being part of the InvolveMENT project team following a presentation 307 that was given at our high school in January 2017 by a researcher (PV). Since then we have had 308 monthly meetings and have been introduced to the field of adolescent mental health research, 309 research terminology and methodology, and the systematic review process. We have also searches. We have asked not to be referred to as "user representatives", as we are not participants 312 in the research and the term can carry stigma. Instead we asked to be referred to as "adolescent 313 representatives". It was later decided we should be re-defined as "co-researchers" as we became 314 more actively involved in the research. For examples, we have carried out a questionnaire survey in 315 cooperation with one of the researchers (PV) to learn about the prevalence of mental disorders and 316 stress in teenagers and their use of mental healthcare services. This research was started in June this 317 year and is still ongoing. We plan to present the results to the students who took part in the survey, 318 teachers and school nurses, and we hope it will help to reduce some of the stigma surrounding 319 mental health and to improve mental health services. 320 321 DISCUSSION 322
323
User involvement has become a priority in healthcare systems in many countries, as it is considered a 324 citizen right to be involved in decisions affecting one's own healthcare. Although several systematic 325 reviews have summarized existing evidence in user involvement in health research for adults in 326 general or in areas such as safety and education of mental health professionals, [39] [40] [41] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We have limited this literature review to adolescents in the age range from 13 to 18 years. It could be 353 argued for a different age span for adolescents, e.g. using UNICEF's definition and the results of this 354 review will not be applicable to children under the age of 13 or young persons above the age of 18 355 years. We do however think that our search strategy will help us to capture most of the relevant 356 literature that is of relevance to user involvement in adolescents' mental healthcare. 357
358
Another limitation of this systematic review is the restriction to only six languages. Although we 359 expect to capture most of the published research literature through English language articles, and 360 although some evidence suggests reduced importance of non-English language articles for assessing 361 the effectiveness of interventions, 42 we cannot exclude the possibility that significant literature has 362 been published in other languages. We have selected six languages in an attempt to limit the gaps in 363 the research evidence collected through our review. Our choice of languages is partly due to the 364 strong tradition user involvement has in some of these countries, but is nevertheless limited by our 365 available resources. The inclusion of a wide range of databases increases the likelihood of capturing 366 most of the relevant literature in this field of research. Moreover, the inclusion a database more 367 specifically covering the Nordic literature will increase the chance of also capturing the evidence 368 published in these countries. 369 370 Our systematic review team includes adolescent co-researchers. Others have suggested public or 371 user involvement may contribute significantly to various stages of the systematic review process.
43-47 372
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METHODS
Eligibility criteria 8
164-184
186-195
STUDY RECORDS
207-211
215-224
166-179
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
229-237
DATA
Synthesis
15a Describe criteria under which study data will be quantitatively synthesized 250-254 15b
If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I
2 , Kendall's tau)
253-262
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